YARS1 and Charcot-Marie-Tooth disease: However, several studies have convincingly shown that for GARS, YARS and AARS, some CMT-associated mutations result in loss of aminoacylation function, whereas others do not affect aminoacylation activity4, 8, 12, 13, 14, 15.